Asset Details
Do you wish to reserve the book?
WHO Classification of Tumours: evolution of a global resource in the molecular era
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
WHO Classification of Tumours: evolution of a global resource in the molecular era
Do you wish to request the book?
WHO Classification of Tumours: evolution of a global resource in the molecular era
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
WHO Classification of Tumours: evolution of a global resource in the molecular era
2025
Overview
Cancer registries, epidemiological studies, national and international health-care initiatives, and clinical, translational, and basic biomedical research rely on this up-to-date classification. [...]it is a broad interdisciplinary, globally harmonised, and sustainable undertaking that reflects health-care systems in both low-income and high-income settings with substantial implications on educational, economic, and political fronts. [...]accurate tumour subtyping when interpreting molecular data, as shown through the current approach of the WCT, is needed to establish the response to specific drug treatment in separate organs. 5 Identification of the site of origin is important in the diagnostic process, even when a tumour has metastasised, as this helps to establish a differential diagnosis and improve treatment selection. The interpretation of molecular tests is influenced by various factors, including tumour heterogeneity, discovery of mutations with uncertain significance, and inaccurate or misinterpreted results. The WCT will build on the existing structural basis and robustly incorporate any clinically validated molecular data during edition revisions.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
